

In the claims:

1. **(Currently amended)** A controlled release pharmaceutical delivery device which provides sustained or pulsatile delivery of a selected pharmaceutically active substance for a predetermined period of time, said device comprising;

- about 1-50% by weight polymers of acrylic acid crosslinked with polyalkenyl alcohols or divinyl ~~alcohol~~alcohol;

- about 1 to 75% by weight of a mixture of hydroxyethyl cellulose and hydroxypropyl methylcellulose;

- about 0<10% by weight talc; and

- about 0<10% by weight magnesium stearate;

wherein said crosslinked polymers, uncrosslinked polymers, talc and magnesium stearate are provided as a matrix.

2. **(Cancelled)**

3. **(Cancelled)**

4. **(Currently amended)** The device of claim 1, wherein said polymers of acrylic acid crosslinked with polyalkenyl alcohols or divinyl ~~alcohol~~alcohol are ~~Carbopol~~carboxyvinyl polymer resins.

5. **(Cancelled)**

6. **(Cancelled)**

7. **(Original)** The device of claim 1, wherein said device additionally comprises about 0.5 to 50% by weight of a coating material comprising anionic polymers based on methacrylic acid and methacrylic acid esters or neutral methacrylic acid esters with trimethylammonioethyl methacrylate chloride or cellulose esters.

8. **(Previously amended)** The device of claim 1, wherein said device additionally comprises 0<95% by weight granulating and tableting aids.

9. **(Currently Amended)** A controlled release pharmaceutical delivery device which provides sustained or pulsatile delivery of a selected pharmaceutically active substance for a predetermined period of time, said device comprising;

- about 1 to less than 50% by weight of a mixture of hydroxyethylcellulose and hydroxypropylmethyl cellulose;
- about 1 to 60% by weight of ethylcellulose;
- about 1 to 80% by weight of at least one ~~Carbopol~~carboxyvinyl polymer resin;
- about 0<10% by weight of talc;
- about 0<10% by weight of magnesium stearate; and
- about 0<95% by weight granulating and tableting aids,

wherein said hydroxyethylcellulose, hydroxypropylmethyl cellulose, ethylcellulose, ~~Carbopol~~carboxyvinyl polymer resin, talc, magnesium stearate and granulating and tableting aid are provided as a matrix.

10. **(Original)** The device of claim 9, wherein said device additionally comprises about 1 to 80% of a pharmaceutically active agent.

11. **(Currently Amended)** The device of claim 10, wherein said pharmaceutically active agent is selected from the group consisting of ~~diltiazem, buspirone, tramadol, gabapentin, verapamil, etodolac, naproxen, diclofenac, COX2 inhibitors, budesonide, venlafaxine, metoprolol, carbidopa, levodopa, carbamazepine, ibuprofen, morphine, pseudoephedrine, paracetamol, cisapride, pilocarpine, methylphenidine, nifedipine, nicardipine, felodipine, captopril, terfenadine, pentoxifylline, fenofibrate, flupizide, aciclovir, zidovudine, moclobemide, potassium chloride, lamotrigine, citalopram, cladribine, loratadine, pancrelipase, lithium carbonate, orphenadrine, ketoprofen, procainamide, ferrous sulfate, risperidone, clonazepam, nefazodone, lovastatin,~~

simvastatin, pravachol, ketorolac, hydromorphone, ticlopidine, seligiline, alprazolam, divalproex and phenytoin.

12. **(Original)** The device as claimed in claim 1 wherein, said device additionally comprises one or more pharmaceutical excipients selected from the group consisting of lactose, silicone dioxide, sodium lauryl sulphate, calcium phosphate, calcium sulphate, silicified microcrystalline cellulose, gelucire® and compritol®.

13-22. **(Withdrawn)**

23. **(Currently amended)** A pharmaceutical composition comprising;

- about 1 to 80% by weight pharmaceutically active agent;
- about 1 to 50% by weight of polymers of acrylic acid crosslinked with polyalkenyl alcohols or divinyl ~~alcohol~~alcohol; and
- about 1 to 75% by weight of a mixture of hydroxyethyl cellulose and hydroxypropyl methylcellulose; wherein said polymers of acrylic acid, hydroxyethyl cellulose and hydroxypropyl methyl cellulose are provided as a matrix.

24-27. **(Cancelled)**

28. **(Original)** The composition of claim 23, wherein said composition additionally comprises about 0.5 to 50% by weight of a pharmaceutically acceptable film coating comprising anionic polymers based on methacrylic acid and methacrylic acid esters or neutral methacrylic acid esters with trimethylammonioethyl methacrylate chloride or cellulose esters.

29. **(Currently amended)** The composition of claim 23, wherein said pharmaceutically active agent is selected from the group consisting of ~~diltiazem, buspirone, tramadol, gabapentin, verapamil, etodolac~~, naproxen, ~~diclofenac~~, COX2 inhibitors, budesonide, venlafaxine, metoprolol, carbidopa, levodopa, carbamazepine, ibuprofen, morphine, pseudoephedrine, paracetamol, cisapride, pilocarpine, methylphenidine, ~~nifedipine~~, nicardipine, felodipine, captopril, terfenadine,

~~pentoxifylline~~, fenofibrate, ~~flipizide~~, aciclovir, zidovudine, moclobemide, potassium chloride, lamotrigine, ~~italopram~~, cladribine, loratadine, pancrelipase, lithium carbonate, orphenadrine, ~~ketoprofen~~, procainamide, ferrous sulfate, risperidone, clonazepam, ~~nefazodone~~, lovastatin, simvastatin, pravachol, ketorolac, hydromorphone, ticlopidine, seligiline, alprazolam, divalproex and phenytoin.

30. **(Currently amended)** A pharmaceutical composition comprising :

- about 1 to 80% pharmaceutically active agent;
- about 1 to 60% by weight of hydroxyethylcellulose;
- about 1 to 75% by weight of hydroxypropylmethyl cellulose;
- about 1 to 60% by weight of ethylcellulose;
- about 1 to 50% by weight of at least one ~~Carbopol~~carboxyvinyl polymer resin;
- about 0<10% by weight of talc;
- about 0<10% by weight of magnesium stearate; and
- about 0< 95% by weight granulating and tableting aids.

31. **(Original)** The composition of claim 30, wherein said tableting and granulating aids are selected from the group consisting of silicone dioxide, lactose, microcrystalline cellulose, calcium phosphate and mannitol.

32. **(Currently amended)** A controlled release pharmaceutical delivery device which provides sustained or pulsatile delivery of a selected pharmaceutically active substance for a predetermined period of time, said device comprising;

- about 1-50% by weight polymers of acrylic acid crosslinked with polyalkenyl alcohols or divinyl ~~alcohol~~alcohol;
- about 1 to 75% by weight of a mixture of hydroxyethyl cellulose and hydroxypropyl methylcellulose; wherein said polymers of acrylic acid, hydroxyethyl cellulose and hydroxypropyl methylcellulose are provided as a matrix;

- about 0.5 to 50% by weight of a coating material coating said matrix, said coating material comprising anionic polymers based on methacrylic acid and methacrylic acid esters or neutral methacrylic acid esters with trimethylammonioethyl methacrylate chloride or cellulose esters.

33. (**Currently amended**) A pharmaceutical composition comprising;

- about 1 to 80% by weight pharmaceutically active agent;
- about 1 to 50% by weight of polymers of acrylic acid crosslinked with polyalkenyl alcohols or divinyl ~~alcohol~~alcohol;
- about 1 to 75% by weight of a mixture of hydroxyethyl cellulose and hydroxypropyl methylcellulose; wherein said polymers of acrylic acid, hydroxyethyl cellulose and hydroxypropyl methylcellulose are provided as a matrix; and

- about 0.5 to 50% by weight of a coating material coating said matrix, said coating material comprising anionic polymers based on methacrylic acid and methacrylic acid esters or neutral methacrylic acid esters with trimethylammonioethyl methacrylate chloride or cellulose esters.